February 11, 2020 10:10 AM EST

Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug

Natalie Grover

Reporter

Once largely overlooked, sickle cell disease (SCD) has recently seen a flurry of approvals. For Pfizer — an SCD drug that has faltered in the pivotal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug

Natalie Grover

Reporter

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Novartis to cut 139 jobs in NJ as part of commercial refocus

Pfiz­er un­cou­ples from Gly­coMimet­ics and its failed sick­le cell dis­ease drug

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Novartis to cut 139 jobs in NJ as part of commercial refocus